Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE: Safety of high-dose intravenous iron isomaltoside 1000 (Monofer) in inflammatory bowel disease
2011-003121-94Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Nov 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ferric derisomaltose in iron deficiency anemia (IDA) and inflammatory bowel disease (IBD), sponsored by Pharmacosmos. Started Nov 2011; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2011-003121-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003121-94.